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Received May 17, 2011; accepted August 15, 2011AbstractEndodermal sinus tumor, also known as yolk sac tumor (YST), is a malignant germ cell tumor that most frequently occurs in the testis, the
ovary, and sacrococcygeal areas in children. YSTs are highly aggressive and because of the early metastatic or invasive pattern, their prognosis
has been poor. Treatment methods for YSTs are usually intensive, including multiagent chemotherapy, and have shown to improve patient
survival significantly; therefore, it is important to consider the reproductive function of these patients with long-term survival. Herein, we present
the case of a 31-year-old female, who was diagnosed with unilateral ovarian YST at the age of 13. The patient was treated with fertility-sparing
surgery and postoperative adjuvant chemotherapy. During the subsequent long-term follow-up, she was not only free of disease, but also had a
successful, naturally conceived pregnancy at 31 years of age. We, therefore, conclude that YST is a curable disease, and that fertility-preser-
vation surgery and subsequent immediate combination chemotherapy is the treatment of choice.
Copyright  2012 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Because of the aggressive nature and occurrence of
malignant germ cell tumor, such as endodermal sinus tumor,
also known as yolk sac tumor (YST),1 on the ovary or the testis
in childhood or in the young adolescent period, greater concern
about future fertility is needed. The feasibility of fertility-
sparing surgery has been discussed at length for decades.2
The main treatment modes are excision or complete removal
of the disease sites by cystectomy, oophorectomy, or unilateral
salpingo-oophorectomy, followed by multiagent chemo-
therapy.3 However, there have been some cases that showed
menstrual disturbance and infertility, suggesting that ovarian
damage or failure was due to the long-term side effects of* Corresponding author. Dr. Peng-Hui Wang, Department of Obstetrics and
Gynecology, Taipei Veterans General Hospital, 201, Section 2, Shih-Pai Road,
Taipei 112, Taiwan, ROC.
E-mail addresses: phwang@vghtpe.gov.tw, phwang@ym.edu.tw (P.-H.
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http://dx.doi.org/10.1016/j.jcma.2012.09.011curative chemotherapy.4 In addition, recurrence of the malig-
nant disease has also been noted in some cases with a curative
status at long-term follow-up. Therefore, many concerns about
the appropriate treatment for patients with malignant germ cell
tumor have been raised. Herein, we present the case of
a female patient who was diagnosed with right ovarian YST,
underwent fertility-sparing surgery and treated with complete
adjuvant chemotherapy at 13 years of age, and who had
a naturally conceived pregnancy at the age of 31.
2. Case report
A 31-year-old femalewas diagnosed with right ovarian YST,
surgicalepathological stage IC, when shewas 13 years old. The
patient underwent right salpingo-oophorectomy, appendec-
tomy, multiple omentum biopsies, and pelvic lymph node
sampling initially, followed by four courses of postoperative
adjuvant chemotherapy with cisplatin, vinblastine, and bleo-
mycin (PVB; 5-day 25-mg cisplatin, 1-day 15-mg vinblastine,
and 1-day 25-mg bleomycin), and then two courses of adjuvanthinese Medical Association. All rights reserved.
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A second-look operation was performed to confirm complete
surgicalepathological remission. After the second-look oper-
ation, two additional courses of adjuvant chemotherapy with
a PV regimen were prescribed. The serum levels of alpha-
fetoprotein decreased from the initial level of 8672 ng/mL
(normal <20 ng/mL) to 2.09 ng/mL after completing eight
courses of adjuvant chemotherapy.
After treatment she had a regular menstrual cycle, and was
able to conceive naturally and give birth to a healthy baby at
39 weeks of gestation at the age of 31.
3. Discussion
YST (endodermal sinus tumor) is the second most common
malignant germ cell tumor of the ovary.5 Before the intro-
duction of effective chemotherapy, the prognosis for patients
diagnosed with YSTs involving surgical treatment was poor.
Patients with YSTs had a 3-year survival rate of 13%.6 After
combination chemotherapy was introduced, the survival rate
improved dramatically.7 However, the standard therapeutic
strategy remains uncertain. Because YSTs are rare and mostly
occur in young girls or adolescents, deciding between pres-
ervation of the reproductive function and achievement of long-
term survival is sometimes difficult.
Fertility-sparing surgery for patients with YSTs was found to
be as effective as radical surgery.8 In addition, malignant germTable 1
The reproductive outcomes of patients with malignant germ cell tumor in five ma
Author/year Histology
(n)
Stage
(n)
Surgery (n) CT
regimen (n)
Fertili
evalua
Kang et al17/2008
(n ¼ 20)
YST (18)
Mixed (2)
I (10)
II (4)
III (6)
USO (15) BEP (20) 20
de La Motte Rouge
et al16/2008 (n ¼ 52)
YST (30)
Mixed (22)
I (34)
II (1)
III (14)
IV (3)
USO (27)
UO (10)
UC (4)
BEP (52) 52
Ayhan et al18/2005
(n ¼ 29)
YST (22)
Mixed (7)
I (16)
II (1)
III (9)
IV (3)
USO (8)
UC (7)
BEP (29) 15
Mitchell et al19/1999
(n ¼ 69)
IT (11)
YST (20)
Mixed (32)
Non-dys (6)
I (35)
II (7)
III (22)
IV (5)
USO (45)
UC (5)
BEP (31)
PVB (11)
CEB (7)
BOP (3)
Others (7)
26
Ezzat et al20/1999
(n ¼ 67)
Dys (33)
IT (18)
YST (10)
Mixed (6)
I/II (44)
III (14)
IV (3)
NA (6)
USO (53) BEP (30)
PVB (9)
Other (28)
44
Attempted pregnancy ¼ attempt to get pregnant; BEP ¼ bleomycin, etoposide, and
CEB ¼ carboplatin, etoposide, and bleomycin; dys ¼ dysgerminoma; IT ¼ imm
non-dys ¼ nondysgerminoma; NA ¼ no data available; PVB ¼ cisplatin, vinblastine
USO ¼ unilateral salpingo-oophorectomy; YST ¼ yolk sac tumor.cell tumors, including YST, removed by conservative operation
and treated with platinum-based chemotherapy might have
excellent survival outcomes.9 Comprehensive staging after
removing localized malignant germ cell tumors of the ovary is
crucial and leads to a better outcome,10 although more conser-
vative procedures, such as cystectomy, might be more beneficial
to maintaining the future reproductive function, based on the
experience of managing ovarian borderline tumors.11,12
However, because all germ cell tumors are highly sensitive to
chemotherapy, we can perform fertility-preservation surgery in
place of debulking surgery, although the risk of chemotherapy-
induced gonadotoxicity should always be kept in mind.13 There
is limited information on the impact of these chemotherapy
regimens on reproductive functionwhenmanaging YSTs. In the
1980s, the PVB regimen demonstrated improved survival rates
with sustained remission in patients with advanced YSTs.14
Later, the bleomycin, etoposide, cisplatin (BEP) combination
appeared to be the most active regimen.15 The effect of the BEP
combination regimen following fertility-sparing surgery for
ovarian YSTs was very good, with a 94% 5-year survival rate
and 90% disease-free survival rate.16 The reproductive
outcomes of patients with malignant germ cell tumor in five
major series are shown in Table 1.16e20 The rate of return to
normal menstruation in all cases was 78% (88/113), and the
overall successful pregnancy rate was 57% (30/53).16e19 In our
case, the right ovarian YST was diagnosed and managed at 13
years of age, just 1 year after her menarche. Conservative andjor series.
ty
tion (n)
Return of
menstruation (n)
Attempted
pregnancy (n)
Pregnancy/
patient (n)
Remarks
15 6 2 Live-birth deliveries
and no complications
39 16 12 Normal pregnancy
with normal
children:
15 of 19 (79%)
Ongoing pregnancy:
1 of 19 (5%)
Miscarriage:
2 of 19 (11%)
Termination:
1 of 19 (5%)
10 5 3 Delivered without
complication
(all live-birth
deliveries)
24 26 11 d
NA d 16 d
cisplatin; BOP ¼ bleomycin, vincristine, and cisplatin; CT ¼ chemotherapy;
ature teratoma; mixed ¼ mixed germ cell tumor; n ¼ number of patients;
, and bleomycin; UC ¼ unilateral cystectomy; UO ¼ unilateral oophorectomy;
114 Y.-W. Chang et al. / Journal of the Chinese Medical Association 76 (2013) 112e114comprehensive staging surgery followed by cisplatin-based
chemotherapy successfully treated this patient. In addition,
the return of her menstrual cycle after treatment suggested
a minimal effect on ovarian function. Finally, the natural
conception with successful term delivery of a healthy fetus
further supported the results of previous studies, summarized in
Table 1, that most patients with comprehensive staging but
fertility-sparing surgery followed by cisplatin-based chemo-
therapy can have an excellent disease-free survival. Thus, it can
be said that ovarian function and future reproductive outcome
can be predicted.
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